Skip to main content

Table 1 Baseline patient demographics and clinical characteristics

From: Quality of life in children and adolescents with bipolar I depression treated with olanzapine/fluoxetine combination

Variable OFC (N = 170) Placebo (N = 85) Total (N = 255)
Age (years), mean (SD) 14.6 (2.3) 15.0 (2.1) 14.7 (2.3)
Sex (male), n (%) 84 (49.4) 46 (54.1) 130 (51.0)
Race (white), n (%) 119 (70.0) 61 (71.8) 180 (70.6)
Ethnicity (hispanic), n (%) 38 (22.4) 23 (27.1) 61 (23.9)
BMI, kg/m2, mean (SD) 23.5 (5.54) 24.0 (5.81) 23.7 (5.62)
Number of previous episodes of depression, median (range) 2.0 (0.0–80.0) 2.0 (0.0–50.0) 2.0 (0.0–80.0)
CDRS-R total score, mean (SD) 54.6 (10.0) 53.7 (8.1) 54.3 (9.4)
YMRS total score, mean (SD) 6.1 (3.8) 6.2 (3.9) 6.1 (3.8)
CGI-BP overall severity, mean (SD) 4.4 (0.7) 4.3 (0.7) 4.4 (0.7)
  1. BMI body mass index, CDRS-R children’s depression rating scale-revised, CGI-BP clinical global impressions-bipolar, N number of patients, OFC olanzapine/fluoxetine combination, SD standard deviation, YMRS Young Mania Rating Scale